The agency plans to fast-track applications for several psychedelics, but it must also create a set of rules about who can take and administer them and in what settings.

By Kamal Choudhury Oct 5 (Reuters) - US health officials are advancing the first government-funded clinical trials of the ...

A pharmaceutical company developing psychedelics as potential medicines recently opened its new United States headquarters in Jersey City, relocating from its former location in Manhattan. Compass ...

Ibogaine clinics in Mexico charge up to $20,000 for psychedelic treatments that carry serious cardiac risks and potentially ...

A study in mice and human tissue suggests psilocybin protects against peripheral neuropathy, a common side effect of chemotherapy. The findings are so promising that researchers are starting a mid-sta ...

A team of USC researchers has received an up to $4 million award from the Advanced Research Projects Agency for Health ...

The cover and title of Rich Haridy’s Trip Reports are reminiscent of a poster for a psychedelic rock band or a 1960s ...

Psychedelic clinical trials present unique challenges that can make successful execution fundamentally different from small molecules. The psychedelic experience, blinding, psychotherapy assistance ...

Food and Drug Administration (FDA) officials are laying out the agency’s “new framework” for psychedelic medicines, including steps that are taking to “make psychedelic therapies available to patients ...

Collaboration will increase access to practitioner education in the United States and internationallyPartnership brings ...

Nashville has never had trouble bringing music, art, and a little rebellion into the same room. Psychedelics, however, remain ...